Don’t Let Promotional Review Processes Slow You Down: Use Data-Driven Strategies for Success

 

In the rapidly evolving landscape of promotional review processes, Vodori’s 2023 State of Promotional Review Benchmarks Report stands as a critical resource for organizations striving to optimize their processes amidst challenges of limited resources and economic constraints. The latest episode of the Benchmarks Symposium, hosted by Annalise Ludtke, the Senior Manager of Marketing and Communications at Vodori, features guest Lindsay Maguera, Customer Success Manager at Vodori. They dive deep into the insights and strategies essential for overcoming these hurdles.

The episode focuses on the best practices highlighted by the 2023 Benchmarks Report, emphasizing the need for organizations to do more with less. Through a detailed conversation, Annalise and Lindsey explore how leveraging data and performance metrics can significantly aid companies in identifying areas for improvement and optimizing their promotional review processes. They discuss practical approaches, such as using premium dashboards to monitor KPIs, improving SOPs, and enhancing the quality of content entering the review system. Additionally, the episode sheds light on specific metrics like job duration, review duration, and the importance of incorporating feedback efficiently to elevate the quality of promotional content.

Lindsey’s insights provide a rich perspective on navigating the challenges of promotional review with a data-driven approach, offering valuable guidance to organizations seeking to maintain high standards of efficiency and quality in their operations. This episode is a must-watch for anyone involved in promotional review processes, offering actionable strategies to thrive in an environment of increasing demands and limited resources.

Recent Episodes

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…